ADA 2026: Hasta La VISTA! Elecoglipron Rounds Out ADA

Research evidence excerpt

ADA 2026: Hasta La VISTA! Elecoglipron Rounds Out ADA

June 9, 2026

of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written

permission of Wolfe Research, LLC.

This report is limited for the sole use of clients of Wolfe Research, LLC, Wolfe Research Securities and Wolfe Research

Advisors, LLC which have been given permission prior to such use. Any distribution of the content produced by Wolfe

Research, LLC will violate the understanding of the terms of our relationship.

You are permitted to store, display, analyze, evaluate, modify, reformat, print and retrieve the information only for your

internal business purposes, and only on your own private and secure system. You cannot resell or reverse engineer the

information, create derivative works or any data, commercial products or other offerings, or calculate or develop any

index for disclosure and/or marketing without the express prior written consent of Wolfe Research. You cannot publish,

transmit, alter, copy, forward, distribute, share, or reproduce the information in any format, or make the information

available in any form or by any means to any third parties, without the express prior written consent of Wolfe Research.

These restrictions include, without limitation: (i) using, extracting, downloading or retrieving this information, in whole

or in part, to train, develop or finetune any artificial intelligence (which includes predictive software or algorithms, neural

networks, machine learning models, large language models and similar technology), or to provide or reproduce this

information, in whole or in part, as a prompt or input to any such artificial intelligence; and (ii) content scraping, automated